Ivacaftor-d18

Ivacaftor-d18 is the deuterium labeled Ivacaftor[1]. Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively[2].

Product Specifications

CAS Number

[1413431-05-6]

Product Name Alternative

VX-770-d18

UNSPSC

12352005

Target

Autophagy; CFTR

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Purity

92.92

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])C(C([2H])([2H])[2H])(C1=C(C=C(C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=C1)O)NC(C2=CNC3=CC=CC=C3C2=O)=O)C([2H])([2H])[2H]

Molecular Formula

C24H10D18N2O3

Molecular Weight

410.60

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Delaunay JL, et al. Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770) . Hepatology. 2017 Feb;65 (2) :560-570.